Skip to content

If you can't switch, better to stay on failing treatment than stop it, studies show

Darunavir European license extended to all treatment-experienced

CD4 decline, death more likely if change from NNRTI regimen delayed

Reduced dose atazanavir safe and effective in small Thai study

Switching to AZT from d4T poses challenges in resource-limited settings

Etravirine (Intelence) approved in Europe for treatment-experienced patients

Uptake of second-line treatment `stagnant` in developing world

Widespread NRTI and NNRTI resistance seen in Malawian patients failing first-line antiretroviral therapy

US study confirms long-term use of AZT, d4T result in lipoatrophy